Logo image of CRSP

CRISPR THERAPEUTICS AG (CRSP) Stock Fundamental Analysis

NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD

37.77  -0.01 (-0.03%)

Premarket: 37.4 -0.37 (-0.98%)

Fundamental Rating

4

Overall CRSP gets a fundamental rating of 4 out of 10. We evaluated CRSP against 568 industry peers in the Biotechnology industry. While CRSP has a great health rating, there are worries on its profitability. CRSP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CRSP has reported negative net income.
CRSP had a negative operating cash flow in the past year.
CRSP had negative earnings in 4 of the past 5 years.
In the past 5 years CRSP reported 4 times negative operating cash flow.
CRSP Yearly Net Income VS EBIT VS OCF VS FCFCRSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.34%, CRSP belongs to the top of the industry, outperforming 81.87% of the companies in the same industry.
CRSP has a Return On Equity of -18.96%. This is amongst the best in the industry. CRSP outperforms 87.50% of its industry peers.
Industry RankSector Rank
ROA -16.34%
ROE -18.96%
ROIC N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
CRSP Yearly ROA, ROE, ROICCRSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

CRSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRSP Yearly Profit, Operating, Gross MarginsCRSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

8

2. Health

2.1 Basic Checks

CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRSP has more shares outstanding
Compared to 5 years ago, CRSP has more shares outstanding
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRSP Yearly Shares OutstandingCRSP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRSP Yearly Total Debt VS Total AssetsCRSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

CRSP has an Altman-Z score of 5.78. This indicates that CRSP is financially healthy and has little risk of bankruptcy at the moment.
CRSP has a better Altman-Z score (5.78) than 82.92% of its industry peers.
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.78
ROIC/WACCN/A
WACC5.15%
CRSP Yearly LT Debt VS Equity VS FCFCRSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 22.07 indicates that CRSP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 22.07, CRSP belongs to the top of the industry, outperforming 96.48% of the companies in the same industry.
CRSP has a Quick Ratio of 22.07. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
CRSP's Quick ratio of 22.07 is amongst the best of the industry. CRSP outperforms 96.48% of its industry peers.
Industry RankSector Rank
Current Ratio 22.07
Quick Ratio 22.07
CRSP Yearly Current Assets VS Current LiabilitesCRSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CRSP have decreased strongly by -122.96% in the last year.
Looking at the last year, CRSP shows a very negative growth in Revenue. The Revenue has decreased by -89.95% in the last year.
CRSP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.62% yearly.
EPS 1Y (TTM)-122.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)-89.95%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%-82.26%

3.2 Future

Based on estimates for the next years, CRSP will show a very strong growth in Earnings Per Share. The EPS will grow by 29.95% on average per year.
The Revenue is expected to grow by 175.16% on average over the next years. This is a very strong growth
EPS Next Y-15.15%
EPS Next 2Y2.07%
EPS Next 3Y10.8%
EPS Next 5Y29.95%
Revenue Next Year269.61%
Revenue Next 2Y275.84%
Revenue Next 3Y216.9%
Revenue Next 5Y175.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRSP Price Earnings VS Forward Price EarningsCRSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRSP Per share dataCRSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.07%
EPS Next 3Y10.8%

More info and screens

0

5. Dividend

5.1 Amount

CRSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (4/17/2025, 8:10:57 PM)

Premarket: 37.4 -0.37 (-0.98%)

37.77

-0.01 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners77.84%
Inst Owner Change0.09%
Ins Owners1.63%
Ins Owner Change0.05%
Market Cap3.26B
Analysts76
Price Target82.24 (117.74%)
Short Float %24.7%
Short Ratio9.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.74%
Min EPS beat(2)30.41%
Max EPS beat(2)63.08%
EPS beat(4)3
Avg EPS beat(4)23.09%
Min EPS beat(4)-5.19%
Max EPS beat(4)63.08%
EPS beat(8)7
Avg EPS beat(8)228.83%
EPS beat(12)9
Avg EPS beat(12)154.29%
EPS beat(16)11
Avg EPS beat(16)126.15%
Revenue beat(2)1
Avg Revenue beat(2)126.18%
Min Revenue beat(2)-91.33%
Max Revenue beat(2)343.7%
Revenue beat(4)1
Avg Revenue beat(4)17.14%
Min Revenue beat(4)-98.14%
Max Revenue beat(4)343.7%
Revenue beat(8)4
Avg Revenue beat(8)532.92%
Revenue beat(12)4
Avg Revenue beat(12)325.91%
Revenue beat(16)6
Avg Revenue beat(16)274.39%
PT rev (1m)-0.9%
PT rev (3m)-0.36%
EPS NQ rev (1m)1.95%
EPS NQ rev (3m)7.68%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)1.74%
Revenue NQ rev (1m)1.28%
Revenue NQ rev (3m)-40.59%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)-58.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.42
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.69
EV/EBITDA N/A
EPS(TTM)-4.37
EYN/A
EPS(NY)-5.03
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.65
OCFYN/A
SpS0.43
BVpS22.37
TBVpS22.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.34%
ROE -18.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.87%
Cap/Sales 5.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.07
Quick Ratio 22.07
Altman-Z 5.78
F-Score3
WACC5.15%
ROIC/WACCN/A
Cap/Depr(3y)74.64%
Cap/Depr(5y)175.56%
Cap/Sales(3y)1036.11%
Cap/Sales(5y)1149.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-122.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
EPS Next Y-15.15%
EPS Next 2Y2.07%
EPS Next 3Y10.8%
EPS Next 5Y29.95%
Revenue 1Y (TTM)-89.95%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%-82.26%
Revenue Next Year269.61%
Revenue Next 2Y275.84%
Revenue Next 3Y216.9%
Revenue Next 5Y175.16%
EBIT growth 1Y-109.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.39%
EBIT Next 3Y15.7%
EBIT Next 5Y22.19%
FCF growth 1Y46.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.17%
OCF growth 3YN/A
OCF growth 5YN/A